Free Trial

TriSalus Life Sciences (TLSI) Stock Price, News & Analysis

TriSalus Life Sciences logo
$4.98 -0.18 (-3.49%)
Closing price 04:00 PM Eastern
Extended Trading
$4.99 +0.01 (+0.20%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About TriSalus Life Sciences Stock (NASDAQ:TLSI)

Key Stats

Today's Range
$4.80
$5.16
50-Day Range
$3.57
$5.45
52-Week Range
$3.42
$5.88
Volume
105,040 shs
Average Volume
66,179 shs
Market Capitalization
$248.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.75
Consensus Rating
Buy

Company Overview

TriSalus Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
67th Percentile Overall Score

TLSI MarketRank™: 

TriSalus Life Sciences scored higher than 67% of companies evaluated by MarketBeat, and ranked 359th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    TriSalus Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    TriSalus Life Sciences has received no research coverage in the past 90 days.

  • Read more about TriSalus Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for TriSalus Life Sciences are expected to grow in the coming year, from ($1.55) to ($0.61) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of TriSalus Life Sciences is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of TriSalus Life Sciences is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about TriSalus Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    3.42% of the float of TriSalus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    TriSalus Life Sciences has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in TriSalus Life Sciences has recently decreased by 5.16%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    TriSalus Life Sciences does not currently pay a dividend.

  • Dividend Growth

    TriSalus Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.42% of the float of TriSalus Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    TriSalus Life Sciences has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in TriSalus Life Sciences has recently decreased by 5.16%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    TriSalus Life Sciences has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.
  • MarketBeat Follows

    3 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, TriSalus Life Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.50% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 2.58% of the stock of TriSalus Life Sciences is held by institutions.

  • Read more about TriSalus Life Sciences' insider trading history.
Receive TLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TLSI Stock News Headlines

Forget Tesla — This Tiny AI Stock Is Musk’s Real Play
While Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it could transform warfare, robotics, and the global economy. But you don’t need to buy Tesla or wait for xAI to IPO to benefit. One overlooked public company is supplying the critical tech behind Musk’s AI push — and it trades for a fraction of Nvidia’s price. Hedge funds are already loading up, but most investors haven’t noticed yet.tc pixel
See More Headlines

TLSI Stock Analysis - Frequently Asked Questions

TriSalus Life Sciences' stock was trading at $5.01 at the start of the year. Since then, TLSI stock has decreased by 0.9% and is now trading at $4.9650.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.05. The business earned $11.21 million during the quarter, compared to analyst estimates of $10.69 million.
Read the conference call transcript
.

Top institutional shareholders of TriSalus Life Sciences include Nantahala Capital Management LLC (5.29%), AWM Investment Company Inc. (3.30%), Gilder Gagnon Howe & Co. LLC (2.89%) and Geode Capital Management LLC (1.20%). Insiders that own company stock include Equity Ab Frankenius, Mary T Szela, George Kelly Martin, Sean Murphy, Bryan F Cox, Richard Marshak, Jodi Devlin, James Emmett Young and Mats Wahlstrom.
View institutional ownership trends
.

Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that TriSalus Life Sciences investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Merck & Co., Inc. (MRK), TJX Companies (TJX), Abacus Health Products (ABAHF) and Airbnb (ABNB).

Company Calendar

Last Earnings
8/12/2025
Today
9/03/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:TLSI
Previous Symbol
NASDAQ:TLSI
CIK
1826667
Fax
N/A
Employees
106
Year Founded
N/A

Price Target and Rating

High Price Target
$12.50
Low Price Target
$10.00
Potential Upside/Downside
+108.3%
Consensus Rating
Buy
Rating Score (0-4)
3.25
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.18)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$30.05 million
Net Margins
-86.61%
Pretax Margin
-86.61%
Return on Equity
N/A
Return on Assets
-116.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.08
Quick Ratio
3.68

Sales & Book Value

Annual Sales
$29.43 million
Price / Sales
8.74
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.39) per share
Price / Book
-13.23

Miscellaneous

Outstanding Shares
49,870,000
Free Float
36,154,000
Market Cap
$257.33 million
Optionable
Not Optionable
Beta
0.49

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:TLSI) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners